



Public Summary of IDG Face-to-Face Meeting

February 26 – 27, 2019

Hyatt Centric Arlington, Senate Ballroom

1325 Wilson Blvd, Arlington, VA 22209

Public Summary:

This annual face-to-face meeting of the IDG consortium involved participation by all the current IDG consortium components (DRGC, KMC, RDOC, and NIH), in addition to NIH External Program Consultants, 8 invited Guest speakers and 3 invited Guests from outside NIH, resulting in attendance of 82 people. Of note, we had two NIH center directors attend (Dr. Griffin Rodgers and Dr. Christopher Austin). The outlined meeting objectives were met; with updates from the different groups, discussions on topics of unmet needs, potential collaborations and synergy. A GoToMeeting teleconference was made available for the meeting which allowed for additional attendees (one EPC member, one IDG member, and different NIH members). More detailed meeting agenda, minutes and links to slides can be requested by contacting ldg.rdoc@gmail.com. Posters presented at the meeting can be viewed at <https://druggablegenome.net/>. Initial feedback from guest attendees was that there was much interest in the work being produced by IDG, and they expressed a desire to find mechanisms of collaboration and build synergies so as to not reproduce work already done.

Areas for future action:

- Find means for going forward with invitation to follow-up teleconference or meetings
 - IDG Outreach meeting with Open Targets in Hinxton, UK on Nov. 15, 2019 (public symposia)
- Extend awareness of protein targets being investigated by IDG
 - Highlight IDG resources (reagents and data) via Pharos and druggablegenome.net Protein Illumination Timeline.
 - Clarify capabilities of DRGC's experimental technologies

External Groups represented at the meeting:

Accelerating Medicine Partnership Type2 Diabetes (AMP T2D)
Accelerating Medicine Partnership Alzheimer's Disease (AMP AD)
Innovative Medicine Initiative (IMI)
NCATS Chemical Genomics Center
OpenTargets
Novartis
UCSF
UniProt